2nd Precision Medicine in Inflammatory Bowel Disease

Memo

Not that much time has passed since our last summit. But a lot has changed. From 2023 to 2024, the industry has made unequivocal advances, from tangible progress using artificial intelligence to robust biomarker development, permitting precise prognosis, astute stratification, and meticulous patient monitoring. Unsurprisingly, this is reflected by countless recent approvals, IND filings, and new companies emerging out of stealth-mode. In this context, the Precision Medicine in Inflammatory Bowel Disease Summit is returning for the second year, as the most comprehensive, ultra-specialized meeting. Uniting over 100 precision medicine in IBD experts, this summit will explore mind-blowing development that will fast-track the optimization of drug development and overcome the one-size-fits-all approach to medicine. URLs:Tickets: https://go.evvnt.com/2069253-2?pid=5569 Brochure: https://go.evvnt.com/2069253-3?pid=5569  Date and Time: On Tue, 19 Mar 2024 08:00 - Thu, 21 Mar 2024 16:00 Venue Details: Hyatt Regency Boston, 1 Avenue de Lafayette, Boston, Massachusetts, 02111, United States Prices:Drug Developer - Focus Day Only: USD 1398.00,Drug Developer - Conference Only: USD 2999.00,Drug Developer - Conference + Focus Day: USD 4197.00,Academic - Focus Day Only: USD 1198.00,Academic - Conference Only: USD 2599.00,Academic - Conference + Focus Day: USD 3597.00,Vendor - Conference Only: USD 3699.00,Vendor - Conference + Focus Day: USD 5097.00 Speakers: Amanda Prince, Associate Director of Immunology, Vedanta Biosciences, Andres Hurtado-Lorenzo, Senior Vice President, Translational Research and IBD Ventures, Crohn's and Colitis Foundation, Ben Kostiuk, Associate Director of Life Science Partnerships, Crohn's and Colitis Foundation, Bradford McRae, Senior Director of Translational Science, Janssen Pharmaceuticals of Johnson and Johnson, Brihad Abhyankar, Senior Vice President, Clinical Development, Morphic Therapeutic, Edward O'Brien, Director, Translational Computational Biology, Seres Therapeutics, Frederic Baribaud, Senior Translational Early Program Lead, Bristol Myers Squibb, Jan Wehkamp, Vice President and Gastroenterology Disease Area Stronghold Lead, Immunology, Janssen Pharmaceuticals, Johnson and Johnson, Jesse Hall, Chief Medical Officer, AltruBio, Kenneth Hung, Senior Director, Inflammatory Bowel Disease/ Gastroenterology Therapeutic Area Lead, Pfizer, Marc Sze, Principal Scientist, Merck and Co, Matthew Staron, Principle Scientist, AbbVie, Mera Telley, Vice President, Genetics and Precision Immunology, Alumis, Miguel Mascarenhas, Gastroenterologist, Centro Hospitalar Sao Joao, Nicole Desch, Principal Scientist, Translational Biomarker Lead, GI Drug Discovery, Takeda, Paul Kayne, Vice President of Biological Sciences, Palatin Technologies, Robert Hirten, Clinical Director; Associate Professor of Medicine and Artificial Intelligence, Icahn School of Medicine at Mount Sinai, Sasha Lukyanov, Senior Director, Data Science, Merck and Co, Scott Snapper, Director, Inflammatory Bowel Disease Center, Boston Children's Hospital, Suryasarathi Dasgupta, Associate Director, Precision Medicine, Immunology, AbbVie, Towia Libermann, Associate Professor of Medicine, Beth Israel Deaconess Medical Centre and Harvard Medical School, Valerie Pivorunas, Scientific Director, Precision Medicine Immunology; Head of Gastroenterology, Abbvie, Vinayagam Arunachalam, Director of Translational Biomarkers, Takeda, Yasmina Bauer, Head of Clinical Biomarkers, Galapagos